HURA trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HURA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, TuHURA Biosciences, Inc. (HURA) has a Wall Street consensus price target of N/A, based on estimates from 3 covering analysts. The company has a market capitalization of $122M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, HURA trades at a trailing P/E of -3.0x. Analysts expect EPS to grow -14.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 KYMRKymera Therapeutics, Inc. | $8.8B | $107.39 | $138.07 | +28.6% | Buy | — | 27 |
 RCUSArcus Biosciences, Inc. | $3.1B | $24.44 | $40.00 | +63.7% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $8.3B | $54.29 | $80.50 | +48.3% | Buy | 55.8x | 13 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 NKTRNektar Therapeutics | $1.4B | $43.58 | $146.00 | +235.0% | Buy | — | 33 |
 CRISCuris, Inc. | $2M | $0.80 | — | — | Buy | — | 18 |
 MGNXMacroGenics, Inc. | $228M | $3.58 | $6.00 | +67.6% | Buy | — | 22 |
 FATEFate Therapeutics, Inc. | $270M | $2.32 | $5.63 | +142.7% | Buy | — | 31 |
 IOVAIovance Biotherapeutics, Inc. | $6.3B | $14.21 | $12.56 | -11.6% | Buy | — | 21 |
Quick answers to the most common questions about buying HURA stock.
The consensus price target for HURA is $N/A, close to the current price of $1.91 (N/A% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
HURA has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
HURA's current price is $1.91 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for HURA, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
HURA is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HURA stock forecast based on 3 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
HURA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HURA analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.